Critical Path Institute to get $20m funding under US Drug Bill proposal
This article was originally published in Clinica
A group of influential Senators have proposed creating a permanent public-private institute within the US FDA for pursuing the goals of the agency's critical path initiative.
You may also be interested in...
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.